- Home
- APTO
as 12-18-2024 11:31am EST
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
| Founded: | 1986 | Country: | Canada |
| Employees: | N/A | City: | TORONTO |
| Market Cap: | 11.5M | IPO Year: | N/A |
| Target Price: | $4.33 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.13 - $2.68 | Next Earning Date: | 11-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aptose Biosciences Inc. (APTO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rice William G. | APTO | Chair, President & CEO | Nov 25 '24 | Buy | $0.20 | 100,000 | $20,000.00 | 613,252 |
Latest Aptose Biosciences Inc. News
APTO Breaking Stock News: Dive into APTO Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Aptose Says Tusepetinib Preclinical Data Published in AACR Journal
GlobeNewswire
6 days ago
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
GlobeNewswire
9 days ago
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
MT Newswires
15 days ago
Aptose Biosciences Links With National Cancer Institute to Develop Tuspetinib in MyeloMATCH Trials
GlobeNewswire
15 days ago
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
MT Newswires
23 days ago
Aptose Biosciences Closes US$8 Million Public Offering
GlobeNewswire
23 days ago
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering
Benzinga
a month ago
S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
Compare APTO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APTO Aptose Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.